Abstract Number: 0373 • ACR Convergence 2025
Implementation of a Lupus Self-Management mHealth App: Using Incentives to Drive Engagement
Background/Purpose: As part of a five-year cooperative agreement with the Centers for Disease Control and Prevention, the Lupus Foundation of America (LFA) has implemented the…Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…Abstract Number: 2646 • ACR Convergence 2025
DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease with significant variability in clinical presentation. DNA methylation has been associated with lupus risk and…Abstract Number: 2561 • ACR Convergence 2025
Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
Background/Purpose: Community-wide access to highly curated, extensive datasets is critical to advance disease understanding and accelerate precision medicine. To address this unmet need in lupus,…Abstract Number: 2457 • ACR Convergence 2025
Maternal, Embryo-Fetal And Neonatal Outcomes Following Belimumab Exposure During Pregnancy In Patients With Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) may be associated with high-risk pregnancies, especially in the presence of specific predisposing factors. While optimal disease control during pregnancy…Abstract Number: 2439 • ACR Convergence 2025
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…Abstract Number: 2420 • ACR Convergence 2025
In-patient Outcomes of Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome in SLE: US National Inpatient Database (2021-2022)
Background/Purpose: Systemic lupus erythematosus (SLE is an autoimmune disease that attacks different organs. There have been reports of hyperglycemic hyperosmolar syndrome (HHS) from steroid use…Abstract Number: 2403 • ACR Convergence 2025
Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Background/Purpose: SLE is clinically heterogeneous and associated with increased hospitalizations. However, it remains unclear which patient subgroups drive this excess in unplanned healthcare use. We…Abstract Number: 2385 • ACR Convergence 2025
The Presence of Avascular Necrosis in Patients with Systemic Lupus Erythematosus Undergoing Total Knee Arthroplasty is Not Associated with Worse Outcomes
Background/Purpose: Systemic lupus erythematosus (SLE) patients seeking total knee arthroplasty (TKA) may present with secondary avascular necrosis (AVN) of the knee due to high-dose glucocorticoid…Abstract Number: 2220 • ACR Convergence 2025
Human Milk Fatty Acid Profiles Among Breastfeeding Mothers With and Without Systemic Autoimmune Rheumatic Diseases
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) are characterized by chronic systemic inflammation and often require…Abstract Number: 1989 • ACR Convergence 2025
Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
Background/Purpose: Young adults with childhood-onset rheumatic conditions encounter challenges and barriers to care when transitioning to an adult rheumatologist. At this Pediatric Rheumatology Clinic, patients…Abstract Number: 1878 • ACR Convergence 2025
Customized Therapy for SLE: How Disease Severity Influences the Use of Corticosteroids and Biologics in Patients with SLE in the Lupus Federated Data Network (LupusNet) and a US Claims Database
Background/Purpose: The management of SLE varies worldwide. Current SLE treatment goals focus on preventing flares, controlling disease activity, and preventing organ damage accrual. LupusNet is…Abstract Number: 1837 • ACR Convergence 2025
Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
Background/Purpose: Systemic lupus erythematosus (SLE) is a predominantly female autoimmune disease, with a 9:1 female-to-male ratio. Our previous studies indicated that increased T-bet+ age-related B…Abstract Number: 1743 • ACR Convergence 2025
Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Background/Purpose: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are associated with chronic inflammation that can accelerate atherosclerosis. There is no specific guidance regarding…Abstract Number: 1690 • ACR Convergence 2025
Environmental Heat Exposure and Risk of Systemic Lupus Erythematosus
Background/Purpose: Environmental heat exposures have been linked to increased morbidity and mortality. Individuals with systemic lupus erythematous (SLE) often have heat- and photo- sensitivity, which…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 181
- Next Page »
